Screening Women With Prior HPV for Anal Neoplasia

Launched by ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI · Jan 31, 2022

Keywords

ClinConnect Summary

This clinical trial is looking at how to better screen for anal cancer precursors in women who have had certain types of HPV-related health issues in the past. The goal is to find effective ways to detect early signs of anal neoplasia, which means abnormal changes that could lead to cancer. The study is specifically for women who are not infected with HIV and have a history of significant HPV-related conditions in the lower genital tract, such as high-grade cervical lesions or previous non-metastatic cancers.

To be eligible for this trial, participants must be women aged 35 and older, with a documented history of high-grade HPV-related diseases. They should also be able to communicate in English or Spanish and have received care at either the Mount Sinai Health System or the Harris Health System in Houston. If you join the trial, you can expect to undergo screening methods aimed at early detection of potential anal cancer, contributing to better health outcomes for women in similar situations. This trial is currently recruiting participants, so there is an opportunity for eligible women to take part in this important research.

Gender

FEMALE

Eligibility criteria

• Inclusion Criteria:
• • Women with a history of pathologically proven high-grade genital HPV-associated neoplastic disease (cervical intraepithelial neoplasia 2+, vulvar intraepithelial neoplasia 2+, or vaginal intraepithelial neoplasia 2+, or history of non-metastatic cervical, vaginal or vulvar cancer)
• • Documented HIV seronegativity
• • Aged 35 years and older
• • Seen in the Mount Sinai Health System (MSHS) or the Harris Health System (HHS) in Houston
• • English or Spanish speaking
• Exclusion Criteria:
• • • prior history or high resolution anoscopy